We are live on ! Find out more
IONS icon

Ionis Pharmaceuticals
IONS

213 hedge funds and large institutions have $4.13B invested in Ionis Pharmaceuticals in 2013 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 83 increasing their positions, 73 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

42% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 24

14% more repeat investments, than reductions

Existing positions increased: 83 | Existing positions reduced: 73

6% more capital invested

Capital invested by funds: $3.91B → $4.13B (+$219M)

4% more funds holding

Funds holding: 204 → 213 (+9)

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

33% less call options, than puts

Call options by funds: $45.9M | Put options by funds: $68.7M

Holders
213
Holders Change
+9
Holders Change %
+4.41%
% of All Funds
6.18%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.15%
New
34
Increased
83
Reduced
73
Closed
24
Calls
$45.9M
Puts
$68.7M
Net Calls
-$22.8M
Net Calls Change
-$4.77M

Top Buyers

1
SAM
Sectoral Asset Management
Quebec, Canada
+$27.8M
2
ACM
Apex Capital Management
Ohio
+$27M
3
WRF
Waddell & Reed Financial
Kansas
+$18M
4
RIM
Rainier Investment Management
Washington
+$18M
5
Wellington Management Group
Wellington Management Group
Massachusetts
+$17.4M

Top Sellers

1
GIM
Granahan Investment Management
Massachusetts
-$31.6M
2
BB
BB Biotech
Switzerland
-$28M
3
PC
PointState Capital
New York
-$27.2M
4
MG
Meditor Group
Bermuda
-$18.4M
5
BA
BlackRock Advisors
Delaware
-$17.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$676M -$1.07M -30,000 -0.2%
Artisan Partners
2
Artisan Partners
Wisconsin
$429M +$5.07M +142,410 +1%
Vanguard Group
3
Vanguard Group
Pennsylvania
$306M +$12.3M +346,234 +5%
ClearBridge Investments
4
ClearBridge Investments
New York
$287M -$638K -17,907 -0.2%
BB
5
BB Biotech
Switzerland
$256M -$28M -785,037 -11%
WRF
6
Waddell & Reed Financial
Kansas
$189M +$18M +506,200 +12%
BFA
7
BlackRock Fund Advisors
California
$168M -$2.36M -66,257 -2%
T. Rowe Price Associates
8
T. Rowe Price Associates
Maryland
$133M -$2.27M -63,630 -2%
BIT
9
BlackRock Institutional Trust
California
$123M +$1.01M +28,364 +0.9%
State Street
10
State Street
Massachusetts
$95.4M -$8.98M -251,984 -10%
PA
11
Pinnacle Associates
New York
$80.3M -$1.72M -48,391 -2%
Jennison Associates
12
Jennison Associates
New York
$76M -$203K -5,710 -0.3%
Franklin Resources
13
Franklin Resources
California
$69.2M -$7.8M -218,926 -11%
Northern Trust
14
Northern Trust
Illinois
$66.3M +$1.55M +43,518 +3%
TAM
15
Tocqueville Asset Management
New York
$66.1M +$11.6K +325 +0%
Lord, Abbett & Co
16
Lord, Abbett & Co
New Jersey
$54.2M -$14.9M -418,379 -24%
EAM
17
Eagle Asset Management
Florida
$52.6M +$14.4M +403,486 +44%
SAM
18
Sectoral Asset Management
Quebec, Canada
$48.7M +$27.8M +781,000 +177%
AllianceBernstein
19
AllianceBernstein
Tennessee
$44.5M -$12.7M -356,777 -24%
BA
20
BlackRock Advisors
Delaware
$33.4M -$17.5M -490,691 -37%
VAM
21
Visium Asset Management
New York
$33.3M +$1.59M +44,575 +6%
Wells Fargo
22
Wells Fargo
California
$30.9M -$276K -7,740 -1%
ACM
23
Apex Capital Management
Ohio
$30.2M +$27M +757,910 New
Norges Bank
24
Norges Bank
Norway
$30M +$912K +25,595 +4%
DY
25
Dowling & Yahnke
California
$26.9M – – –
1
2 3 4 5

IONS Hedge Fund Activity: Q4 2013 in Review

213 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q4 2013, worth a combined $4.13B — up 5.6% from $3.91B a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new IONS positions and 24 closed out — a net gain of 10 holders — while 83 added to existing stakes and 73 trimmed.

The largest buyer was Sectoral Asset Management, adding an estimated $27.8M. The largest seller was Granahan Investment Management, exiting entirely with an estimated $31.6M sold.

  • 213 institutional investors held Ionis Pharmaceuticals (IONS) as of Q4 2013, up from 204 in Q3 2013.
  • Funds reported $4.13B of Ionis Pharmaceuticals stock for Q4 2013, up 5.6% quarter-over-quarter.
  • 34 funds opened new Ionis Pharmaceuticals positions in Q4 2013 and 24 closed out, a net change of +10 holders.
  • The largest Ionis Pharmaceuticals buyer in Q4 2013 was Sectoral Asset Management, an estimated $27.8M added.
  • The largest Ionis Pharmaceuticals seller in Q4 2013 was Granahan Investment Management, an estimated $31.6M sold.

Based on aggregated 13F filings for Q4 2013.